Get the latest market trends in your inbox
Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
Gingko Bioworks' lab facility. Photo: Gingko Bioworks
Ginkgo Bioworks is in the business of designing and printing microbes, but it recently raised $275 million — bringing its valuation to over $1 billion — because it sees itself more akin to a software company.
Why it matters: The Boston-based company says that, by providing specialized services for designing, developing, and printing DNA, it can open possibilities for customers in industries outside of health care.
For example, a fragrance company can pay Ginkgo Bioworks for a project that would otherwise be too expensive to do in-house, according to co-founder and CEO Jason Kelly. A pharma company would have to hire scientists to do the development itself.
Deal details: Investors in the round include Viking Global, Y Combinator's Continuity Fund, Cascade Investment (Bill Gates' investment vehicle), and General Atlantic. Though Kelly declined to specify the new valuation, a Delaware filing first spotted by Recode pegs it at $1.3 billion.
Part of the proceeds will be used to open a third lab facility.